Recordkeeping fees per participant
not reported
Not reported on this filing.
Employers › Apellis Pharmaceuticals
Apellis Pharmaceuticals 401(k)
- Manufacturing
- Waltham, MA
- EIN 27-1537290
- 1 plan with Schedule H financials
- Plan year 2024
- Apellis Pharmaceuticals, Inc.
Filed as negative.Schedule H line 2i(3) is reported as -$4,659. The filing is shown as received; the derived figures below treat a negative amount as zero, and a percentile is only shown for positive values.
Total assets, end of year · Apellis Pharmaceuticals, Inc. 401(k) Plan · plan year 2024
$88,038,236
761 participants with a balance. This filing reports no recordkeeping fee and no administrative expenses excluding investment management, so there is no headline cost figure.
Source
Schedule H, Part I line 1f col (b); TOT_ASSETS_EOY_AMT pos 61; filing 20250926102137NAL0003946307001, received 2025-09-26
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20250926102137NAL0003946307001, received 2025-09-26
Percentiles compare this plan with the Schedule H plans $50 to 250M in assets of the same plan year, excluding final filings; shown only where at least 50 comparable plans report the figure. Plan year 2024-01-01 to 2024-12-31, filing received 2025-09-26.
Cost and contributions
Administrative expenses excluding investment management, per participant
$0.00
Fewer than 50 comparable plans report this figure; no percentile.
Source
= $0 / 761
derived, admin_expenses (2i(12)) minus invst_mgmt_fees (2i(5)), floored at 0; filing 20250926102137NAL0003946307001, received 2025-09-26
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20250926102137NAL0003946307001, received 2025-09-26
Administrative expenses per participant
$4.16
Higher than 1% of the 9,042 plans $50 to 250M that report it.
Source
= $3,166 / 761
Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20250926102137NAL0003946307001, received 2025-09-26
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20250926102137NAL0003946307001, received 2025-09-26
Administrative expenses as a share of assets
0.004%
Higher than 2% of the 9,049 plans $50 to 250M that report it.
Source
= $3,166 / $88,038,236
Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20250926102137NAL0003946307001, received 2025-09-26
assets_eoy: Schedule H, Part I line 1f col (b); TOT_ASSETS_EOY_AMT pos 61; filing 20250926102137NAL0003946307001, received 2025-09-26
Employer contributions per participant
$6,717
Higher than 86% of the 9,105 plans $50 to 250M that report it.
Source
= $5,111,972 / 761
Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20250926102137NAL0003946307001, received 2025-09-26
participants_with_balance: Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20250926102137NAL0003946307001, received 2025-09-26
Employer share of total contributions
23.0%
Higher than 28% of the 9,112 plans $50 to 250M that report it.
Source
= $5,111,972 / $22,197,126
Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20250926102137NAL0003946307001, received 2025-09-26
total_contrib: Schedule H, line 2a(3); TOT_CONTRIB_AMT pos 72; filing 20250926102137NAL0003946307001, received 2025-09-26
Plan terms, as stated in Apellis Pharmaceuticals, Inc.'s SEC filings
Plan terms are described in Apellis Pharmaceuticals, Inc.'s SEC filings: Form 10-K filed 2026-02-24. No term could be quoted from them with the required precision.
Plan features
2E profit-sharing · 2G fully participant-directed · 2J 401(k) feature · 2K 401(m) arrangement · 2F ERISA 404(c) plan · 2T default investment (QDIA) · 3D IRS pre-approved plan · 2R participant brokerage window · Form 5500, line 8a; TYPE_PENSION_BNFT_CODE pos 81; filing 20250926102137NAL0003946307001, received 2025-09-26
Full record, Apellis Pharmaceuticals, Inc. 401(k) Plan
| Field | Value | Source |
|---|---|---|
| Plan sponsor | APELLIS PHARMACEUTICALS, INC. | Form 5500, Part II line 2a; SPONSOR_DFE_NAME pos 19; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Plan name | APELLIS PHARMACEUTICALS, INC. 401(K) PLAN | Form 5500, line 1a; PLAN_NAME pos 16; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Sponsor EIN / plan number | 27-1537290 / 001 | Form 5500, line 2b; SPONS_DFE_EIN pos 44; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Plan type | single-employer | Form 5500, Part I line A; TYPE_PLAN_ENTITY_CD pos 4; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Sponsor location | WALTHAM, MA | Form 5500, line 2a; SPONS_DFE_MAIL_US_STATE pos 25; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Industry (business code) | 325410, Manufacturing | Form 5500, line 2d; BUSINESS_CODE pos 46; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Plan year | 2024-01-01 to 2024-12-31 | Form 5500, Part I plan year; FORM_PLAN_YEAR_BEGIN_DATE pos 2; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Filing received | 2025-09-26 | Form 5500, EFAST2 receipt date; DATE_RECEIVED pos 102; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Final filing | no | Form 5500, Part I line B; FINAL_FILING_IND pos 8; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Amended filing | no | Form 5500, Part I line B; AMENDED_IND pos 7; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Participants, beginning of year | 818 | Form 5500, line 5; TOT_PARTCP_BOY_CNT pos 71; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Active participants | 615 | Form 5500, line 6a(2); TOT_ACTIVE_PARTCP_CNT pos 72; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Participants, end of year | 805 | Form 5500, line 6f; TOT_ACT_RTD_SEP_BENEF_CNT pos 77; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Participants with an account balance | 761 | Form 5500, line 6g(2); PARTCP_ACCOUNT_BAL_CNT pos 78; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Total assets, beginning of year | $65,013,917 | Schedule H, Part I line 1f col (a); TOT_ASSETS_BOY_AMT pos 30; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Total assets, end of year | $88,038,236 | Schedule H, Part I line 1f col (b); TOT_ASSETS_EOY_AMT pos 61; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Net assets, end of year | $88,038,236 | Schedule H, line 1l col (b); NET_ASSETS_EOY_AMT pos 67; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Total income | $32,809,023 | Schedule H, Part II line 2d; TOT_INCOME_AMT pos 97; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Net income | $23,024,319 | Schedule H, line 2k; NET_INCOME_AMT pos 111; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Employer contributions | $5,111,972 | Schedule H, Part II line 2a(1)(A); EMPLR_CONTRIB_INCOME_AMT pos 68; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Participant contributions | $11,511,081 | Schedule H, line 2a(1)(B); PARTICIPANT_CONTRIB_AMT pos 69; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Other contributions (incl. rollovers) | $5,574,073 | Schedule H, line 2a(1)(C); OTH_CONTRIB_RCVD_AMT pos 70; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Total contributions | $22,197,126 | Schedule H, line 2a(3); TOT_CONTRIB_AMT pos 72; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Benefit payments | $9,756,344 | Schedule H, line 2e(4); TOT_DISTRIB_BNFT_AMT pos 101; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Total expenses (incl. benefit payments) | $9,784,704 | Schedule H, line 2j; TOT_EXPENSES_AMT pos 110; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Total administrative expenses | $3,166 | Schedule H, line 2i(12) total administrative expenses; TOT_ADMIN_EXPENSES_AMT pos 109; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Contract administrator fees | $0 | Schedule H, line 2i(2); CONTRACT_ADMIN_FEES_AMT pos 106; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Recordkeeping fees | -$4,659 (filed as negative) | Schedule H, line 2i(3); OTH_RECORDKEEPING_FEES_AMT pos 160; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| IQPA audit fees | $0 | Schedule H, line 2i(4); IQPA_AUDIT_FEES_AMT pos 161; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Investment advisory and management fees | $7,825 | Schedule H, line 2i(5); INVST_MGMT_FEES_AMT pos 107; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Administrative expenses excluding investment management | $0 | derived, admin_expenses (2i(12)) minus invst_mgmt_fees (2i(5)), floored at 0; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Held in master trusts | $0 | Schedule H, line 1c(11) col (b); INT_MASTER_TR_EOY_AMT pos 53; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Held in common/collective trusts | $0 | Schedule H, line 1c(9) col (b); INT_COMMON_TR_EOY_AMT pos 51; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Held in mutual funds | $86,028,818 | Schedule H, line 1c(13) col (b); INT_REG_INVST_CO_EOY_AMT pos 55; filing 20250926102137NAL0003946307001, received 2025-09-26 |
| Independent auditor | GRAY GRAY AND GRAY, LLP | Schedule H, Part III line 3a; ACCOUNTANT_FIRM_NAME pos 116; filing 20250926102137NAL0003946307001, received 2025-09-26 |
Position = column in the DOL layout for form year 2024. Filing 20250926102137NAL0003946307001, received 2025-09-26.
Service providers paid directly by the plan
| Provider | Relationship | Service codes | Direct compensation | Indirect |
|---|---|---|---|---|
| STRATEGIC ADVISORS, INC. | ADVISOR | 27 Investment advisory (plan) | $7,825 | no |
| FIDELITY INVESTMENTS INSTITUTIONALrecordkeeper | RECORDKEEPER | 37 Participant loan processing; 64 Recordkeeping fees; 65 Account maintenance fees; 71 Securities brokerage commissions and fees | $-4,524 | yes |
Schedule C Part I line 2: name (a), service codes (b), relationship (c), direct compensation paid by the plan (d), indirect compensation received (e). Filing 20250926102137NAL0003946307001, received 2025-09-26.
What changed since the 2023 plan year
| Figure | 2023 | 2024 | Change |
|---|---|---|---|
| Total assets | $65,013,917 | $88,038,236 | 35.4% |
| Participants with a balance | 790 | 761 | -3.7% |
| Administrative expenses | $5,716 | $3,166 | -44.6% |
| Recordkeeping fees per participant | $3.66 | not reported | |
| Employer contributions | $5,602,857 | $5,111,972 | -8.8% |
Prior filing 20241010122731NAL0020967121001, received 2024-10-10; the plan years are contiguous.
Alerts, claims and corrections
Sponsor name as filed: APELLIS PHARMACEUTICALS, INC.; SEC registrant: Apellis Pharmaceuticals, Inc. (CIK 1492422, matched by EIN; display name from the Form 10-K cover).